Publication | Closed Access

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

Diabetes ManagementInsulin DegludecDiabetesPharmacologyClinical TrialsType 2Fixed-ratio CombinationInsulin ManagementPharmacotherapyDiabetes MellitusInsulin DeliveryMedicine